EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a unit conversion tool for five quantitative anti‐spike assays and agreement analysis of three qualitative anti‐nucleocapsid assays for SARS‐CoV‐2

Serge Ouoba, Aya Sugiyama, Ko Ko, Ulugbek Khudayberdievich Mirzaev, Kanon Abe, Bunthen E, Zayar Phyo, Kobiljon Khusniddin Khalilov, Akemi Kurisu, Tomoyuki Akita, Kazuaki Takahashi, Hiroshi Sasaki und 2 weitere

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Serge Ouoba und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiros…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Antibodies, Viral, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Commercially available assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) anti‐spike (S) or anti‐nucleocapsid (N) antibodies differ in units, making results comparisons challenging. This study aimed to develop conversion equations between five quantitative anti‐S antibody tests and to assess the agreement over time between three qualitative anti‐N antibody tests. Blood samples from 24 216 vaccinated healthcare workers in Hiroshima Prefecture, Japan, were analyzed for anti‐S antibodies using five quantitative tests (Abbott, Fujirebio, Ortho, Sysmex, Roche) and for anti‐N antibodies using three qualitative tests (Abbott, Sysmex, Roche). Geometric mean regression was performed to establish equations for converting measured values between the five quantitative tests. Fleiss κ statistic was used to assess the agreement between the three qualitative tests. A strong correlation (Pearson's coefficient r > 0.9) was found for each pair of the five quantitative tests measuring anti‐S antibodies, enabling the development of equations to convert values between each pair. Using these equations, which are based on the original output unit of each test, values obtained from one test can be transformed to be equivalent to the corresponding values in another test. For the three tests for anti‐N antibodies, the agreement was substantial in the total sample (Fleiss' κ , 0.74) and moderate among those with self‐reported past coronavirus disease 2019 (COVID‐19) infection (Fleiss' κ , 0.39). The agreement decreased with time after infection. Reduced agreement between anti‐N antibodies tests over time suggests caution in comparing seroepidemiological studies of COVID‐19 exposure based on anti‐N antibodies measurement. The findings could help improve antibody measurement systems and inform public health decision‐makers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusAntibodies, ViralCOVID-19SARS-CoV-2COVID-19 Serological TestingHumansJapanCoronavirus Nucleocapsid ProteinsHealth PersonnelPhosphoproteins

Stichwörter der Autor:innen

SARS‐CoV‐2agreementantibodyconversion

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, Viralspike protein, SARS-CoV-2Coronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteins

Autor:innen und Institutionen

  • Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Science de la Santé (IRSS), Nanoro, Burkina Faso.
  • Department of Hepatology, Scientific Research Institute of Virology, Ministry of Health, Tashkent, Uzbekistan.
  • National Payment Certification Agency, Ministry of Economy and Finance, Phnom Penh, Cambodia.
  • Hiroshima City Medical Association Clinical Laboratory, Hiroshima, Japan.

ORCID-Profile: Junko Tanaka

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Ouoba, S., Sugiyama, A., Ko, K., Mirzaev, U. K., Abe, K., E, B., Phyo, Z., Khalilov, K. K., Kurisu, A., Akita, T., Takahashi, K., Sasaki, H., Yamamoto, T., & Tanaka, J. (2024). Development of a unit conversion tool for five quantitative anti‐spike assays and agreement analysis of three qualitative anti‐nucleocapsid assays for SARS‐CoV‐2. Journal of Medical Virology. https://doi.org/10.1002/jmv.29826

Vancouver

Ouoba S, Sugiyama A, Ko K, Mirzaev UK, Abe K, E B, et al. Development of a unit conversion tool for five quantitative anti‐spike assays and agreement analysis of three qualitative anti‐nucleocapsid assays for SARS‐CoV‐2. Journal of Medical Virology. 2024. doi:10.1002/jmv.29826

BibTeX
@article{Ouoba2024,
  author = {Ouoba, Serge and Sugiyama, Aya and Ko, Ko and Mirzaev, Ulugbek Khudayberdievich and Abe, Kanon and E, Bunthen and Phyo, Zayar and Khalilov, Kobiljon Khusniddin and Kurisu, Akemi and Akita, Tomoyuki and Takahashi, Kazuaki and Sasaki, Hiroshi and Yamamoto, Takumi and Tanaka, Junko},
  title = {Development of a unit conversion tool for five quantitative anti‐spike assays and agreement analysis of three qualitative anti‐nucleocapsid assays for SARS‐CoV‐2},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29826}
}
Kostenlos starten →